Drug Trial Radar · NCT05442190
Topical SGX302 for Mild-to-Moderate Psoriasis
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Dec 14, 2022
Primary completion
Oct 22, 2025
Study completion Nov 17, 2025
Sponsor
- Lead sponsor
- SoligenixIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Conditions
- Psoriasis
- Plaque Psoriasis
- Psoriasis Vulgaris
Interventions
HypericinDrug
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment ScaleTime frame: 18 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Therapeutics Clinical Research
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.